Core A will fulfill three major functions. One function is the overall management of the POI, which will be the responsibility of the Pl (Steven Balk) and the co-investigator (Peter Nelson). They will insure that administrative and regulatory requirements are met, but their main focuses will be on enhancing communication and collaboration between the Projects and on optimizing the use of the resources provided by the P01. The second function of the Core is to assist the Projects in efforts to translate their findings into patients. In addition to Drs. Balk and Nelson, Core A includes three investigators with a major focus on the design and conduct of clinical trials in prostate cancer (Drs. Mary-Ellen Taplin, Bruce Montgomery, and Glenn Bubley). Through previous/ongoing clinical trials and tissue banking efforts at their respective institutions, these investigators have collected valuable tissue and serum samples from patients at varying stages of their disease and after varying therapies. In discussions with the Project Leaders, they will facilitate the identification and distribution of relevant coded clinical samples for analysis by the Projects, and will assist in interpreting the clinical significance of the results. Moreover, Drs. Taplin, Montgomery and Bubley will assist the Project Leaders in the design and conduct of preclinical studies that can form the foundation for subsequent phase I or phase 11 clinical trials. The third Core function is to provide statistical support for each of the Project Leaders in their experimental designs. Lillian Werner, in the Department of Biostatistics and Computational Biology at DFCI, who also directs the DF/HCC Prostate Cancer SPORE Biostatistics and Computational Biology Core, is dedicating 10% effort specifically to this P01.
The specific aims are:
Aim 1. Provide administrative support to insure that the goals of the project are achieved.
Aim 2. Assist in translating the results from each Project into the clinic.
Aim 3. Provide biostatistical support for each Project.
The objectives of Core A are to 1) provide administrative support to insure that the goals of the project are achieved;2) assist in translating the results from each Project into the clinic;and 3) provide biostatistical support for each Project.
|Penning, Trevor M (2017) Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review. Expert Opin Ther Pat 27:1329-1340|
|Sowalsky, Adam G; Kissick, Haydn T; Gerrin, Sean J et al. (2017) Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res 23:3823-3833|
|Green, S M; Kaipainen, A; Bullock, K et al. (2017) Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis 20:20-27|
|Suominen, Mari I; Fagerlund, Katja M; Rissanen, Jukka P et al. (2017) Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23:4335-4346|
|Bluemn, Eric G; Coleman, Ilsa M; Lucas, Jared M et al. (2017) Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell 32:474-489.e6|
|Mostaghel, Elahe A; Cho, Eunpi; Zhang, Ailin et al. (2017) Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res 23:4592-4601|
|Zou, Min; Toivanen, Roxanne; Mitrofanova, Antonina et al. (2017) Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discov 7:736-749|
|Nyquist, Michael D; Prasad, Bhagwat; Mostaghel, Elahe A (2017) Harnessing Solute Carrier Transporters for Precision Oncology. Molecules 22:|
|Nyquist, Michael D; Corella, Alexandra; Burns, John et al. (2017) Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Mol Cancer Res 15:521-531|
|Zang, Tianzhu; Tamae, Daniel; Mesaros, Clementina et al. (2017) Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry. J Steroid Biochem Mol Biol 165:342-355|
Showing the most recent 10 out of 74 publications